Please login to the form below

Not currently logged in
Email:
Password:

tenofovir

This page shows the latest tenofovir news and features for those working in and with pharma, biotech and healthcare.

GSK’s says depot HIV injection works over three years

GSK’s says depot HIV injection works over three years

drug tablet Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide).

Latest news

  • Janssen’s single tablet Symtuza gains NHS England funding  Janssen’s single tablet Symtuza gains NHS England funding 

    Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide [D/C/F/TAF]).is once-daily darunavir-based single tablet regimen (STR), for the treatment of HIV-1 infection in adults and adolescents aged ... Biktarvy is a combination of integrase

  • ViiV chalks up another win for two-drug HIV regimen ViiV chalks up another win for two-drug HIV regimen

    effects. Last month for example, ViiV showed that an oral formulation of Tivicay with nucleoside RTI Epivir (lamivudine) was as effective as a three-drug cocktail of dolutegravir plus tenofovir disoproxil ... Gilead’s new fixed-dose Biktarvy

  • GSK two-drug trial in untreated HIV raises Gilead rivalry GSK two-drug trial in untreated HIV raises Gilead rivalry

    The combination of integrase inhibitor Tivicay (dolutegravir) with nucleoside reverse transcriptase inhibitor Epivir (lamivudine) had similar efficacy to treatment with dolutegravir plus tenofovir disoproxil fumarate and emtricitabine – two

  • Gilead’s Biktarvy gets European approval, setting up battle with GSK Gilead’s Biktarvy gets European approval, setting up battle with GSK

    The single tablet regimen (STR) is a combination of integrase inhibitor bictegravir with Gilead’s already blockbuster Descovy, a combination of emtricitabine (FTC) and tenofovir alafenamide (TAF).

  • The year of the blockbuster The year of the blockbuster

    Biktarvy (tenofovir alafenamide emtricitabine bictegravir) from Gilead:Gilead’s HIV triplet comprising the nucleoside reverse transcriptase inhibitor tenofovir alafenamide, the nucleoside reverse transcriptase inhibitor emtricitabine and the novel

More from news
Approximately 10 fully matching, plus 98 partially matching documents found.

Latest Intelligence

  • Choices, choices: the rapidly evolving HIV treatment landscape Choices, choices: the rapidly evolving HIV treatment landscape

    With Triumeq signalling the approval of the first STR without tenofovir disoproxil fumarate (TDF) it can, uniquely, be used in those patients with impaired kidney function. ... Gilead, in hot pursuit, is in phase III of development of a new regimen where

  • Pharma deals during July 2012 Pharma deals during July 2012

    Merck has licensed CMX 157 an oral nucleoside reverse transcriptase inhibitor for treatment of HIV that is 200-fold more potent in vitro than tenofovir (Gilead's product with sales of

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics